Unassociated Document
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of report (Date of earliest event
reported): May 29, 2009
Neuralstem, Inc.
(Exact name of registrant as specified
in Charter)
|
Delaware
|
|
000-1357459
|
|
52-2007292
|
|
(State or other jurisdiction
of
incorporation or
organization)
|
|
(Commission File
No.)
|
|
(IRS Employee Identification
No.)
|
9700
Great Seneca Highway, Rockville, Maryland 20850
(Address of Principal Executive
Offices)
(301)
366-4841
(Issuer Telephone
number)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 7.01 Regulation FD
Disclosure.
On May
27, 2009, I. Richard Garr, Chief Executive Officer of Neuralstem, Inc. (the
“Company”) issued a letter to the Company’s shareholders discussing the
Company’s anticipated clinical trial. The letter will also be
distributed to the Company’s shareholders, along with the Proxy Statement and
Annual Report, in connection with the upcoming July 2, 2009 Annual
Meeting. A copy of the letter is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
The
information contained in this Current Report on Form 8-K and the exhibits
attached hereto shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, nor shall such information
or such exhibits be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. The information set
forth in or exhibits to this Form 8-K shall not be deemed an admission as to the
materiality of any information in this report on Form 8-K that is required to be
disclosed solely to satisfy the requirements of Regulation FD.
Item
9.01 Financial Statement and Exhibits.
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
99.1
|
|
Letter
Dated May 27, 2009 to the Company’s
shareholders
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report on Form 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.
|
NEURALSTEM,
INC
|
|
|
|
|
|
By:
|
|
/s/
I. Richard Garr
|
|
|
|
I.
Richard Garr
Chief Executive
Officer
|